Argenica Therapeutics (ASX:AGN) EBITDA Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AGN Argenica Therapeutics Ltd ASX:AGN
30 GF Score
Price A$0.14
! 1 Warning Sign
View Full Analysis

What is Argenica Therapeutics EBITDA Margin %?

Argenica Therapeutics ASX:AGN +12.00% 30 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates ASX:AGN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, Argenica Therapeutics ranks worse than 106496.17% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Argenica Therapeutics's EBITDA for the six months ended in Dec. 2025 was A$-3.82 Mil. Argenica Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Argenica Therapeutics's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Argenica Therapeutics  (ASX:AGN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Argenica Therapeutics EBITDA Margin % Related Terms

Argenica Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Argenica Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argenica Therapeutics EBITDA Margin % Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
0.00 0.00 0.00 0.00 0.00

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:AGN vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Argenica Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argenica Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argenica Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Argenica Therapeutics's EBITDA Margin % falls into.


ASX:AGN
30GF Score
Argenica Therapeutics Ltd ASX:AGN
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Argenica Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Argenica Therapeutics's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-7.17/0
= %

Argenica Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.817/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Argenica Therapeutics (ASX:AGN) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Argenica Therapeutics and its competitors. According to the industry distribution chart, Argenica Therapeutics ranks #999999 out of 939 companies in the Biotechnology industry.
Is Argenica Therapeutics' EBITDA Margin % too high?
Argenica Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Argenica Therapeutics ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Argenica Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Argenica Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Argenica Therapeutics ranks #999999 out of 939 companies for EBITDA Margin %. This places Argenica Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Argenica Therapeutics and its competitors. Argenica Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argenica Therapeutics stock overvalued right now?
Argenica Therapeutics (ASX:AGN) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Argenica Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Argenica Therapeutics (ASX:AGN), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argenica Therapeutics Business Description

Address 117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
30GF Score

Get the complete analysis for ASX:AGN

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price